


Sorensis Pty Ltd

The Cattle Contraception Company

Exacting science. Enduring Solutions

Dr Kim Agnew CEO/Founder





Vast nature — no boundaries

Wet season — stock cannot move easily

Impacts of Unmanaged breeding

Annual Impact on the Australian Cattle industry

750,000+

Cattle affected annually

Cull Cattle

400,000

Surgically sterilized
annually

Allows market access
Surgical sterilisation is invasive
and painful,

**Heifer Supply
Chain**

350,000

Unwanted pregnancies

Multiple pregnancy checks,
abortifacients,
Reduced growth

**Mid Tier
Enterprises**

90% (at risk)

Producers with
limited options

Unmanaged breeding
Preventable losses and
Reduced productivity

DIY Cattle Contraception

Producer applied implant that **reduces labour** costs, **returns time** to the producer, and effectively **prevents** unwanted pregnancies.




Implant

Concept only

How does it work?

Blocks signals from brain to ovary
Ovaries do not release fertile eggs




Site of application



Applicator

Concept only

How big is the opportunity?




End User Value

Reproductive Management *

Operations Management**

Estimated \$ 175/hd return



Mortality

- Reduce cull cattle mortality
- Reduce calf mortality

Reproductive efficiency

- Reduce out of season calves
- Improved heifer retention

Labour saving

- Producer applied
- Treat and cull at same time


*Ref: MLA B.AHW.0181 (Weight gain, Round up cost, Livetrade premium)


*Spay costs: Dr P Letchford (pers.comms) (Based on 65:35% split (heifers/cows))

**Chang et al. The Rangeland Journal, 2020,42, 9-26

**b.nbp.0382_final_report Cash Cow beef fertility project

PROJECT TRACTION






First Customer – Strategic Why

Co-create solutions with major customers

Validate economics

Validate demand



>100,000 head




Potential first customer



Pastoral Company


Efficacy/Safety in vivo POC study

((POC) Proof of Concept)



POC Data drives Strategic Pivot


Un optimised implants



- **Phase 2**
 - 12-month product (Market expansion)



- **Phase 1**
 - 6-month product (Reduced time to market)



POC Safety – Body weight & Implant site

	Mean weight (kg)					Mean wt change (kg)
	Day 0	1 month	2 month	3 month	4 month	19/06/2025
Control	407.6	436.8	444.2	462.6	459.2	51.6
Prototype 1	374.3	399.8	410.5	429.8	428.9	54.6
Prototype 2	378.9	411.3	417	434	436.6	57.7
Placebo	380	398.6	413	432	428.8	48.8

Safety Summary

- **Body weight** – no indication of adverse effects on weight gain
- **Implant site** – no serious adverse events seen at implant site

Commercial Forecast

Australia/US/Latin America

2030

	AUS/US/Brazil Combined forecast						
	Year 1	Year 2	Year 3	Year 4	Year 5	Year 6	Year 7
Revenue (\$USD)	\$640,000	\$3,840,000	\$7,010,000	\$13,930,000	\$20,991,000	\$27,044,000	\$31,433,000
COGS	\$256,000	\$1,536,000	\$2,804,000	\$5,572,000	\$8,396,400	\$10,817,600	\$12,573,200
Gross Profit	\$384,000	\$2,304,000	\$4,206,000	\$8,358,000	\$12,594,600	\$16,226,400	\$18,859,800
EBITDA	\$192,000	\$1,152,000	\$2,103,000	\$4,179,000	\$6,297,300	\$8,113,200	\$9,429,900

Assumptions

- Sales revenue
- COGs @40%
- EBITDA – 50% Gross profit

US entry

Brazil entry

Distribution






Dr Kim Agnew
CEO / Founder
Sorensis



Dr Rob Hunter
CSO
Sorensis



Shawn Gliner
CEO / Founder
Pendant Biosciences



Prof. Michael D'Occhio
University of Sydney



Dr Peter Letchford
Veterinary surgeon
and consultant



Katherine Teh
Director / Founder
Futureye

A person wearing a white shirt, light blue jeans, and a wide-brimmed hat is riding a dark horse through a field of tall grass. They are surrounded by a large herd of cattle. The scene is set at sunset, with a warm, golden light. Overlaid on the image are several callout boxes: two yellow ovals at the top left, a blue oval below them, a blue cloud-like shape at the top right, and a blue rectangular box at the bottom center.

**FIRST
CUSTOMER**

**INDUSTRY
VALIDATION**

**FUNDING
\$US6,000,000**

**Commercialisation
Partner**

**Dr Kim Agnew
CEO/Founder Sorensis
+61 438 073 708
kim.agnew@sorensis.com**